Baker Bros. Advisors Lp Buys Seagen Inc, Prelude Therapeutics Inc, Kymera Therapeutics Inc, Sells Seagen Inc, Principia Biopharma Inc, Neurocrine Biosciences Inc

• New Purchases: SGT, PRLD, KYMR, PACB, ATHA, HRMY, AKRO, TCRR, INZY, GTH,
• Added Positions: BGNE, GBT, KOD, HZNP, ASND, CBAY, ALBO, NLTX, REPL, ALKS, ALT, OVID,
• Reduced Positions: NBIX, INSM, AMRN, MYOK, FMTX, GWPH, BCRX, RYTM, PTGX, AXSM, ADAP, NVAX, QURE, EVFM, ALLK, ARAV, AUPH, ISEE, KRYS, CCXI, IMMU, RCUS, DNLI, KZR, FLGT, AUTL, CRNX, UROV, GMDA, ORTX, ALEC, NGM, APLT, ADPT, KRTX, MIRM, OYST, PASG, LEGN, BNR, VKTX, GLPG, CPRX, BLUE, XLRN, XNCR, DRNA, GLMD, ADMS, LPTX, AFMD, IFRX, XENE, MTEM, CHMA, SNSS, SGMO, NTLA, RETA, ANAB, VXRT,
• Sold Out: SGEN, PRNB, TCDA, AIMT, ABEO, MTNB, ARYA, MRKR,

For the details of BAKER BROS. ADVISORS LP's stock buys and sells, go to https://www.gurufocus.com/guru/baker+bros.+advisors+lp/current-portfolio/portfolio

1. Seagen Inc (SGT) - 47,269,424 shares, 37.19% of the total portfolio. New Position
2. BeiGene Ltd (BGNE) - 13,301,597 shares, 15.32% of the total portfolio. Shares added by 12.94%
3. Incyte Corp (INCY) - 31,999,398 shares, 11.54% of the total portfolio.
4. ACADIA Pharmaceuticals Inc (ACAD) - 41,904,586 shares, 6.95% of the total portfolio.
5. Alexion Pharmaceuticals Inc (ALXN) - 8,760,794 shares, 4.03% of the total portfolio.

Baker Bros. Advisors Lp initiated holding in Seagen Inc. The purchase prices were between $123.22 and $162.9, with an estimated average price of $141.98. The stock is now traded at around $144.20. The impact to a portfolio due to this purchase was 37.19%. The holding were 47,269,424 shares as of .

Baker Bros. Advisors Lp initiated holding in Prelude Therapeutics Inc. The purchase prices were between $26.2 and $30.13, with an estimated average price of $28.24. The stock is now traded at around $46.91. The impact to a portfolio due to this purchase was 1.23%. The holding were 10,118,636 shares as of .

Baker Bros. Advisors Lp initiated holding in Kymera Therapeutics Inc. The purchase prices were between $26.1 and $33.28, with an estimated average price of $30.49. The stock is now traded at around $45.81. The impact to a portfolio due to this purchase was 0.25%. The holding were 1,959,211 shares as of .

Baker Bros. Advisors Lp initiated holding in Pacific Biosciences of California Inc. The purchase prices were between $3.61 and $9.87, with an estimated average price of $5.74. The stock is now traded at around $14.41. The impact to a portfolio due to this purchase was 0.13%. The holding were 3,250,000 shares as of .

Baker Bros. Advisors Lp initiated holding in Athira Pharma Inc. The purchase prices were between $16.02 and $18.46, with an estimated average price of $16.7. The stock is now traded at around $23.30. The impact to a portfolio due to this purchase was 0.07%. The holding were 882,352 shares as of .

Baker Bros. Advisors Lp initiated holding in Harmony Biosciences Holdings Inc. The purchase prices were between $30.96 and $44.39, with an estimated average price of $36.62. The stock is now traded at around $46.65. The impact to a portfolio due to this purchase was 0.05%. The holding were 400,000 shares as of .

Baker Bros. Advisors Lp added to a holding in Global Blood Therapeutics Inc by 1858.24%. The purchase prices were between $52.76 and $74.49, with an estimated average price of $63.55. The stock is now traded at around $43.57. The impact to a portfolio due to this purchase was 0.19%. The holding were 920,375 shares as of .

Baker Bros. Advisors Lp added to a holding in Horizon Therapeutics PLC by 233.25%. The purchase prices were between $55.23 and $79.93, with an estimated average price of $68.64. The stock is now traded at around $69.04. The impact to a portfolio due to this purchase was 0.15%. The holding were 666,500 shares as of .

Baker Bros. Advisors Lp added to a holding in CymaBay Therapeutics Inc by 113.59%. The purchase prices were between $3.32 and $7.24, with an estimated average price of $5.33. The stock is now traded at around $7.19. The impact to a portfolio due to this purchase was 0.05%. The holding were 3,252,542 shares as of .

Baker Bros. Advisors Lp added to a holding in Replimune Group Inc by 3918.40%. The purchase prices were between $18.85 and $27, with an estimated average price of $22.78. The stock is now traded at around $48.50. The impact to a portfolio due to this purchase was 0.02%. The holding were 206,586 shares as of .

Baker Bros. Advisors Lp added to a holding in Albireo Pharma Inc by 48.77%. The purchase prices were between $23.19 and $41.61, with an estimated average price of $29.06. The stock is now traded at around $35.77. The impact to a portfolio due to this purchase was 0.02%. The holding were 549,047 shares as of .

Baker Bros. Advisors Lp added to a holding in Ovid Therapeutics Inc by 28.92%. The purchase prices were between $5.39 and $8.24, with an estimated average price of $6.68. The stock is now traded at around $6.12. The impact to a portfolio due to this purchase was less than 0.01%. The holding were 590,761 shares as of .

Baker Bros. Advisors Lp sold out a holding in Seagen Inc. The sale prices were between $145.95 and $195.69, with an estimated average price of $167.15.

Baker Bros. Advisors Lp sold out a holding in Principia Biopharma Inc. The sale prices were between $56 and $101.07, with an estimated average price of $88.57.

Baker Bros. Advisors Lp sold out a holding in Tricida Inc. The sale prices were between $8.56 and $26.93, with an estimated average price of $14.73.

Baker Bros. Advisors Lp sold out a holding in Aimmune Therapeutics Inc. The sale prices were between $11.99 and $34.45, with an estimated average price of $21.43.

Baker Bros. Advisors Lp sold out a holding in Abeona Therapeutics Inc. The sale prices were between $1.02 and $3.42, with an estimated average price of $2.52.

Baker Bros. Advisors Lp sold out a holding in Matinas BioPharma Holdings Inc. The sale prices were between $0.67 and $0.96, with an estimated average price of $0.79.